Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study-Reference-Cited by-同舟云学术

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Published:2021-11 Issue:11 Volume:22 Page:1541-1559
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Saad Fred,Efstathiou Eleni,Attard Gerhardt,Flaig Thomas W,Franke Fabio,Goodman Oscar B,Oudard Stéphane,Steuber Thomas,Suzuki Hiroyoshi,Wu Daphne,Yeruva Kesav,De Porre Peter,Brookman-May Sabine,Li Susan,Li Jinhui,Thomas Shibu,Bevans Katherine B,Mundle Suneel D,McCarthy Sharon A,Rathkopf Dana E

Funder

Janssen Research and Development LLC

Publisher

Elsevier BV

Subject

Oncology

Reference40 articles.

1. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019);James;Eur Urol,2015

2. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer;Schalken;BJU Int,2016

3. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer;Yamaoka;Clin Cancer Res,2010

4. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone;Efstathiou;J Clin Oncol,2012

5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer;European Journal of Cancer;2024-09

2. HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES;Cell Reports Medicine;2024-08

3. Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials;Clinical Genitourinary Cancer;2024-06

4. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial;European Urology;2024-06

5. Synthesis and Biological Evaluation of Methoxypolyethylene-Glycol-Substituted Abiraterone Derivatives as Potential Antiprostate Cancer Agents;Molecular Pharmaceutics;2024-05-30